>
抗原抗體、ELISA、WB >
一抗 >
Polyclonal Antibodies >
OPRM1 / Mu Opioid Receptor Antibody (N-Terminus)品牌 |
Leading Biology | 貨號(hào) |
AMM06915G |
產(chǎn)品分類 |
Polyclonal Antibodies | 研究領(lǐng)域 |
|
產(chǎn)品概述 |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality OPRM1 / Mu Opioid Receptor antibody (N-Terminus).
|
||
分子量 |
45kDa
|
||
細(xì)胞定位 |
Antigen Cellular Localization:
Cell membrane; Multi-pass membrane protein
|
||
宿主 |
Rabbit
|
||
種屬反應(yīng)性 |
Human
|
||
靶點(diǎn) |
Human OPRM1 / Mu Opioid Receptor. BLAST analysis of the peptide immunogen showed no homology with other human proteins.
|
||
通用名 |
MOR1
|
||
基因ID |
|||
UniProt ID |
|||
功能 |
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta- gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist- specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding- competent OPRM1 isoforms and reduce their ligand binding activity.
|
||
總結(jié) |
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta- gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist- specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding- competent OPRM1 isoforms and reduce their ligand binding activity.
|
||
形式 |
Liquid
|
||
儲(chǔ)存條件 |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
應(yīng)用 |
IHC-P
|
||
稀釋方法 |
IHC-P (10 μg/ml)
|
||
別名 |
Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP, OPRM1, MOR1
|
||
圖像 |
Anti-OPRM1 / Mu Opioid Receptor antibody AMM06915G IHC of human brain, cerebellum. |
||
說(shuō)明書 |
|||
數(shù)量 |
|
選擇 | 品牌 | 貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 | 分類 | 研究領(lǐng)域 | 說(shuō)明書 | 數(shù)量 | 目錄價(jià) | |
1 | Leading Biology | APR05963G | EGFR Antibody (Y1092) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購(gòu) 詢價(jià) | ||
2 | Leading Biology | APR03116G | BRCA1 Antibody (aa1847-1863) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購(gòu) 詢價(jià) | ||
3 | Leading Biology | AMM05633G | Bombesin Receptor 2 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購(gòu) 詢價(jià) | ||
4 | Leading Biology | APR10986G | AP3B1 Antibody (aa2-14) | 50 μg | Polyclonal Antibodies |
|
¥4950.00 | 訂購(gòu) 詢價(jià) | ||
5 | Leading Biology | APR11512G | Bestrophin-1 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購(gòu) 詢價(jià) | ||
6 | Leading Biology | APG01407G | A3 Adenosine Receptor Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購(gòu) 詢價(jià) |
微信掃描二維碼,隨時(shí)隨地與小諾親密接觸,精彩活動(dòng),勁爆優(yōu)惠,觸手可得!